Publication: Antitumor
effect of intratumoral administration
of dendritic cell combination with vincristine
chemotherapy in a murine fibrosarcoma model
Authors
Shin, J.Y. ; Lee, S.K. ; Kang, C.D. ; Chung, J.S. ; Lee, E.Y. ; Seo, S.Y. ; Lee, S.Y. ; Baek, S.Y. ; Kim, B.S. ; Kim, J.B. ; Yoon, S.
item.page.secondaryauthor
item.page.director
Publisher
Murcia : F. Hernández
publication.page.editor
publication.page.department
DOI
item.page.type
info:eu-repo/semantics/article
Description
Abstract
A new antitumor therapeutic strategy
utilizing the combined effect of chemotherapy and DC
(dendritic cell)-based immunotherapy was designed, and
the effect of intratumoral injections of unpulsed,
immature DCs was evaluated after in vivo pretreatment
of vincristine on tumor growth in a murine fibrosarcoma
tumor model.
Vincristine exerted a much more potent
apoptosis/necrosis-inducing effect on MCA-102 tumor
cells than on DCs both in vitro and in vivo. Moreover,
CD11c, CD40, CD80 and CD86 molecules on DCs were
not downregulated after treatment with vincristine either
in vitro or in vivo. The growth of tumor significantly
regressed in the group which received the combined
vincristine chemotherapy with intratumoral
administration of DCs in contrast to the untreated group,
the group treated with DCs alone, and the group treated
with vincristine alone. In particular, an upregulated
expression of CD40, CD80 and CD86 molecules on DCs
was found in the combination treatment group.
Furthermore, the number of CD4+ and CD8+ T cells and
the staining intensity of their CD4 and CD8 surface
molecules also increased after the combination
treatment.
Therefore, our results indicate the feasibility of this
combination therapy with vincristine chemotherapy and
DC-based immunotherapy as an efficient antitumor
strategy for the treatment of fibrosarcoma.
publication.page.subject
Citation
item.page.embargo
Ir a Estadísticas
Sin licencia Creative Commons.